Bank of America Securities reaffirms their Buy rating on Haemonetics (HAE). Nov. 7, 2026, 12:36 AM In a report released yesterday, Travis Steed from Bank of America Securities maintained a Buy rating on Haemonetics. The company's shares closed yesterday at $119.93. According to TipRanks, Steed is a 4-star analyst with an average return of 4.5% and a 56.82% success rate. Steed covers the Healthcare sector, focusing on stocks such as Medtronic, Abbott Laboratories, and Becton Dickinson. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Haemonetics with a $139.57 average price target, which is a 16.38% upside from current levels. In a report released yesterday, Barrington also maintained a Buy rating on the stock with a $145.00 price target. Based on Haemonetics' latest earnings release for the quarter ending September 26, the company reported a quarterly revenue of $357.76 million and a net profit of $46.31 million. In comparison, last year the company earned a revenue of $327.32 million and had a net profit of $38.68 million Read More on HAE:

Haemonetics Q2 earnings call highlights. Haemonetics (NYSE:HAE) raised its fiscal 2027 revenue growth outlook after reporting double-digit organic growth in its second quarter, but lowered its operating margin expansion forecast as it invests to support an expanded relationship with plasma collector CSL. The company reported 10% organic revenue growth for the quarter and 8% for the first half of the fiscal year. Adjusted earnings per share rose 6% to $1.35 in the quarter and 6% to $2.49 for the first half, Chief Executive Officer Chris Simon said on the earnings call. Haemonetics now expects fiscal 2027 organic revenue growth of 6% to 9%, up from its prior forecast of 4% to 7%. It raised its reported revenue growth outlook to 8% to 11% from 5% to 8% and expects adjusted earnings per diluted share growth in line with the new reported revenue range. At the same time, the company reduced its forecast for adjusted operating margin expansion to 0 to 50 basis points from 50 to 100 basis points. Chief Financial Officer James D'Arecca cited spending ahead of plasma share gains, higher performance-based compensation and continuing cost pressures. CSL rollout drives investment plans. Simon said Haemonetics expects to complete the rollout of its NexSys PCS system with Persona PLUS to all of CSL's U.S. plasma centers before the end of calendar 2027. He said CSL will also use the company's updated software offerings. The fiscal 2027 outlook includes completed CSL center conversions and those formally confirmed through the end of the fiscal third quarter. Simon said the company expects additional conversions in the fourth quarter but has not included them in guidance pending confirmation of specific plans. He declined to disclose customer-specific contract economics, citing confidentiality and competition. Haemonetics' plasma revenue grew 18% organically in the second quarter and 13% in the first half, helped by prior share gains, collections growth and Persona PLUS adoption. D'Arecca said CSL contributed minimally to the second-quarter result. The company raised its full-year apheresis organic revenue growth forecast to high single digits from low to mid-single digits. Simon said the outlook does not assume incremental revenue from second-half plasma collections growth. U.S. collections trended in the mid- to high-single digits during the quarter and first half, while collections outside the U.S. grew well into the double digits, he said. D'Arecca said Haemonetics will need to expand manufacturing capacity and purchase additional devices, resulting in elevated capital expenditures over the next two years. He expects some ramp-up costs to be transitory, with greater fixed-cost absorption as volumes increase in fiscal 2028 and beyond. MedSurg growth and product launches. MedSurg organic revenue grew 6% in both the quarter and first half. Blood Management Technologies grew 7% in the quarter, while Interventional Technologies grew 3%. Simon said vascular closure led the latter segment's performance, partially offset by a difficult prior-year comparison in esophageal cooling. Haemonetics reaffirmed its forecast for mid-single-digit MedSurg organic revenue growth in fiscal 2027. Simon said recent product and regulatory milestones are not expected to contribute materially to revenue this year. Those milestones include U.S. Food and Drug Administration approval for PerQseal Elite, a vascular closure product for large-bore procedures, and the launch of the PacePro guidewire. Simon said the products were in the early stages of launch and that the company would take a stepwise approach to PerQseal Elite, emphasizing physician education and training. Margins and cash flow. Second-quarter adjusted gross margin rose approximately 140 basis points to 61.9%, including an approximately 200-basis-point benefit from tariff refunds and a 60-basis-point foreign exchange headwind. Excluding those two factors, gross margin was essentially flat, D'Arecca said. Adjusted operating expenses rose 15% to $127.6 million in the quarter, reflecting growth investments, personnel costs and higher freight expenses. Adjusted operating margin fell 40 basis points to 26.3%. D'Arecca said second-half margin expansion is expected to be weighted toward the fourth quarter, in line with the anticipated revenue cadence. First-half operating cash flow increased 40% to $180 million, while free cash flow rose approximately 57% to $143 million. Haemonetics ended the quarter with approximately $261 million in cash and estimated net leverage of approximately 2.5 times EBITDA, as defined in its credit agreement. About Haemonetics (NYSE:HAE). Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care. The company's offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.

Haemonetics raises fiscal 2027 organic revenue growth outlook to 6% to 9%. Second-quarter organic revenue rose 10% in the period ended Sept. 26, 2026. CSL expects its U.S. center rollout to finish by the end of 2027. Published Nov 7, 2026, 1:51 AM EST Haemonetics lifted its fiscal 2027 organic revenue growth outlook Thursday, Nov. 5, 2026, after second-quarter organic revenue rose 10%, while reducing its expected adjusted operating margin expansion for the year. Discover more Editorial archive access Market prediction tools The new forecast sets organic revenue growth at 6% to 9%, up from 4% to 7%. The reported revenue growth range now stands at 8% to 11%, versus the prior 5% to 8%. Haemonetics projects high-single-digit organic growth in Apheresis and mid-single-digit growth in MedSurg. Its fiscal year ends April 3, 2027. Revenue for the quarter ended Sept. 26, 2026, totaled $357.8 million, a 9.3% increase from a year earlier. Organic revenue increased 13.6% in Apheresis and 5.5% in MedSurg. Haemonetics' organic growth measure removes currency fluctuations and the effect of exiting certain liquid solution products. The revenue outlook increase came with a narrower margin forecast. Haemonetics now expects adjusted operating margin expansion of 0 to 50 basis points, down from its previous 50-to-100-basis-point range. It projects adjusted earnings per diluted share to grow at a pace comparable to reported revenue growth, with free cash flow conversion above 80%. The comparison underlying the organic revenue outlook also includes nominal historical Vivasure revenue from before its acquisition. This affects the comparison period used for the growth forecast. CSL expects the NexSys PCS devices, which use Persona PLUS technology, to reach its U.S. plasma collection centers by the end of calendar 2027. Haemonetics said CSL currently expects the transition to include all its existing U.S. centers. The rollout could change in scope or timing, with implementation details still unresolved. The expected completion date is part of the CSL rollout timeline. Haemonetics entered a non-exclusive supply agreement with CSL on Aug. 14, 2026. It covers CSL's use of the devices and purchases of related U.S. disposable supplies, with no minimum purchase commitments. Discover more Crypto market analysis Blockchain news subscription Daily crypto news Haemonetics CEO Chris Simon said the CSL expansion and recent product milestones in Apheresis and MedSurg "strengthen our competitive position and create powerful new opportunities." John Kim. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to [email protected].